Prostatic Cysts and Paraprostatic Cysts

Prostatic cysts are fluid-filled cavities within the prostate gland, arising from the prostatic parenchyma, ducts, or acini. Paraprostatic cysts are large, fluid-filled structures located adjacent to or surrounding the prostate, often connected to the gland by a stalk or arising from remnants of the Mullerian duct (uterus masculinus) or other embryological structures. These cysts can be congenital or acquired, and they may be single or multiple, ranging from a few millimeters to massive sizes that occupy a significant portion of the caudal abdomen. In dogs, prostatic cysts are commonly associated with benign prostatic hyperplasia (BPH) and are often sterile, but they can become infected, leading to abscessation. Paraprostatic cysts are less common and may be discovered incidentally or due to clinical signs related to their size, such as tenesmus, dysuria, or constipation. In cats, prostatic cysts are rare but can occur, often associated with androgen-secreting tumors or congenital anomalies. The clinical significance of these cysts lies in their potential to cause lower urinary tract obstruction, gastrointestinal compression, and secondary bacterial infection, which can be life-threatening if not managed appropriately.

The etiology of prostatic and paraprostatic cysts is multifactorial. Prostatic cysts are most commonly associated with benign prostatic hyperplasia (BPH), which is driven by chronic androgen stimulation, particularly dihydrotestosterone (DHT), and estrogen imbalance. In BPH, the glandular and stromal elements proliferate, and cystic dilation of acini can occur due to obstruction of ducts. Retention cysts may also form secondary to inflammation, fibrosis, or neoplasia. Paraprostatic cysts are often congenital, arising from remnants of the Mullerian duct (uterus masculinus) or the prostatic utricle, which are embryological structures that normally regress. In some cases, they may be acquired due to trauma, surgery, or chronic prostatitis. Bacterial infection can be a primary or secondary event, with common pathogens including Escherichia coli, Staphylococcus spp., Streptococcus spp., and Mycoplasma spp. In cats, prostatic cysts may be associated with testosterone-secreting interstitial cell tumors or other androgen-producing neoplasms. Iatrogenic causes include surgical trauma or improper catheterization. Genetic predisposition has been suggested in certain breeds, but specific genetic markers have not been fully characterized.

Prostatic cysts are primarily a disease of intact male dogs, with a higher prevalence in older animals (typically >6 years of age) due to the increased incidence of BPH. Breeds such as the Doberman Pinscher, German Shepherd, and Boxer may be overrepresented, but any breed can be affected. Paraprostatic cysts are less common and may be seen in younger dogs, sometimes as congenital anomalies. The incidence of prostatic cysts in dogs is not precisely known, but BPH is estimated to affect up to 80% of intact male dogs over 5 years of age, and a significant proportion of these may develop cystic changes. In cats, prostatic cysts are extremely rare, with only sporadic case reports, often associated with testicular neoplasia or congenital abnormalities. There is no sex predilection in cats, but the condition is typically seen in intact males. Breeding status is a significant factor: castration reduces the risk of BPH and associated cysts, but paraprostatic cysts may persist or even enlarge after castration if they are not hormonally responsive. The disease is not contagious and has no known zoonotic potential.

The pathophysiology of prostatic cysts is closely linked to hormonal imbalances. In intact male dogs, testosterone is converted to DHT by the enzyme 5-alpha-reductase within the prostate. DHT binds to androgen receptors, stimulating proliferation of glandular epithelial cells and stromal fibroblasts, leading to BPH. As the gland enlarges, ducts may become obstructed, leading to accumulation of prostatic fluid and formation of retention cysts. These cysts are typically lined by cuboidal or columnar epithelium and contain a clear, serous fluid. In some cases, cysts may become infected, leading to abscessation, which is characterized by purulent exudate and necrosis. Paraprostatic cysts, on the other hand, are often derived from embryological remnants. The uterus masculinus, a remnant of the Mullerian duct, is located in the dorsal aspect of the prostate and can dilate to form a large cyst. These cysts may have a fibrous wall and may be lined by cuboidal or transitional epithelium. They can grow to enormous sizes, causing compression of the urethra, colon, and other pelvic organs. In cats, prostatic cysts may be associated with androgen-secreting tumors, leading to excessive DHT production and glandular hyperplasia with cystic degeneration. The presence of cysts can disrupt normal prostatic function, including seminal fluid production, and may lead to infertility. Additionally, large cysts can cause mechanical obstruction of the urinary and gastrointestinal tracts, leading to clinical signs such as dysuria, stranguria, and tenesmus.

Intrinsic predisposing factors include age (older intact males), breed (certain breeds may have a genetic predisposition), and hormonal status (intact males with high testosterone and DHT levels). Congenital anomalies, such as persistent Mullerian duct remnants, predispose to paraprostatic cysts. Extrinsic factors include the use of exogenous androgens or anabolic steroids, which can exacerbate BPH and cyst formation. Poor breeding management, such as prolonged periods of sexual rest, may increase the risk of prostatic congestion and cyst development. Trauma to the pelvic region or iatrogenic injury during catheterization or surgery can also predispose to cyst formation. Additionally, chronic bacterial prostatitis can lead to ductal obstruction and cyst formation. In cats, the presence of testicular neoplasia is a significant risk factor. Environmental factors such as stress and poor hygiene may contribute to secondary infections, but they are not primary causes.

Clinical signs of prostatic and paraprostatic cysts vary depending on the size, location, and presence of infection. Many small cysts are asymptomatic and are discovered incidentally during routine examination or imaging. When clinical signs are present, they may include: - Stranguria, dysuria, or hematuria due to urethral compression or irritation. - Tenesmus and constipation due to compression of the colon or rectum. - Abdominal distension or a palpable caudal abdominal mass. - Pain on palpation of the prostate or abdomen. - Stiff gait or reluctance to move, especially in cases of prostatic pain. - Systemic signs such as fever, lethargy, and anorexia if the cyst is infected or abscessed. - Purulent or sanguineous urethral discharge. - Infertility or poor semen quality due to prostatic dysfunction. - In severe cases, acute urinary obstruction or rupture of the cyst, leading to peritonitis. On rectal palpation, the prostate may be symmetrically or asymmetrically enlarged, fluctuant, or painful. Paraprostatic cysts may be felt as a large, fluid-filled mass in the caudal abdomen, often separate from the prostate.

Differential diagnoses for prostatic and paraprostatic cysts include: 1. Benign prostatic hyperplasia (BPH): Diffuse prostatic enlargement without discrete cysts; imaging shows homogeneous parenchyma. 2. Prostatic abscess: Focal or multifocal cavitary lesions with purulent content; often associated with systemic signs and pain. 3. Prostatic neoplasia (adenocarcinoma, transitional cell carcinoma): Irregular, invasive mass with possible metastasis; cytology/histopathology is definitive. 4. Paraprostatic cyst: Large, fluid-filled mass adjacent to the prostate; may be congenital or acquired. 5. Prostatic cystadenoma: Rare benign tumor with cystic components. 6. Urachal cyst: Remnant of the urachus, located cranially to the bladder, not associated with the prostate. 7. Seminal vesiculitis (in other species, but rare in dogs): Inflammation of the seminal vesicles, which are not present in dogs. 8. Perineal hernia: Soft tissue swelling in the perineal region, often reducible, with a different anatomical location. 9. Abdominal neoplasia (e.g., leiomyoma, lipoma): Mass effect may mimic a paraprostatic cyst. 10. Prostatic retention cyst: A single cyst within the prostate, often associated with BPH. Definitive diagnosis relies on imaging (ultrasonography, radiography, CT/MRI), cytology, and histopathology.

The diagnostic approach to prostatic and paraprostatic cysts should be systematic: 1. History and physical examination: Obtain a thorough history, including signalment, reproductive status, and clinical signs. Perform abdominal palpation and rectal palpation to assess prostatic size, symmetry, and pain. 2. Laboratory tests: Complete blood count (CBC), serum biochemistry, and urinalysis to assess for infection, inflammation, and organ dysfunction. 3. Imaging: Abdominal radiography may reveal a soft tissue mass in the caudal abdomen, but ultrasonography is the preferred modality. Ultrasonography can differentiate between prostatic cysts (anechoic, well-defined cavities within the prostate) and paraprostatic cysts (large, fluid-filled masses adjacent to the prostate). It can also assess the prostate for BPH, abscesses, or neoplasia. 4. Prostatic fluid evaluation: If prostatic fluid can be obtained via ejaculation or prostatic massage, it should be submitted for cytology and bacterial culture. 5. Fine-needle aspiration (FNA): Ultrasound-guided FNA of the cyst can be performed to obtain fluid for cytology and culture. This is particularly useful for paraprostatic cysts. 6. Biopsy: If neoplasia is suspected, a biopsy (tru-cut or surgical) should be obtained for histopathology. 7. Advanced imaging: CT or MRI may be indicated for complex cases, especially to assess the extent of the cyst and its relationship to surrounding structures. 8. Urethrocystoscopy: May be useful to evaluate the prostatic urethra and rule out other causes of lower urinary tract signs.

Laboratory findings in prostatic and paraprostatic cysts are often nonspecific. CBC may show leukocytosis with a left shift if there is secondary bacterial infection or abscessation. Serum biochemistry may be normal, but in cases of urinary obstruction, azotemia (elevated BUN and creatinine) may be present. Urinalysis may reveal hematuria, pyuria, or bacteriuria if the cyst communicates with the urethra or if there is concurrent urinary tract infection. Prostatic fluid analysis (from ejaculate or prostatic massage) may show increased numbers of neutrophils, macrophages, and bacteria if infected. Cytology of cyst fluid obtained via FNA typically shows acellular, proteinaceous fluid with few inflammatory cells if sterile; if infected, it may contain degenerate neutrophils and bacteria. Culture and sensitivity of the fluid should be performed to guide antibiotic therapy. Hormonal assays (testosterone, DHT) are not routinely indicated but may be useful in cases of suspected androgen-secreting tumors in cats.

Imaging is crucial for the diagnosis and characterization of prostatic and paraprostatic cysts. Abdominal radiography may show a soft tissue mass in the caudal abdomen, but it is not specific. Ultrasonography is the most valuable imaging modality. On ultrasound, prostatic cysts appear as well-defined, anechoic (fluid-filled) cavities within the prostatic parenchyma. They may be single or multiple, and the prostate may be enlarged due to concurrent BPH. Paraprostatic cysts appear as large, anechoic masses adjacent to the prostate, often with a thin or thick wall. They may be located cranially, dorsally, or laterally to the prostate. Ultrasonography can also help guide FNA or biopsy. In cases of abscessation, the cyst content may appear echogenic or have a fluid-debris level. Color Doppler can assess vascularity, which is typically absent in cysts but may be present in neoplasia. CT and MRI provide excellent anatomical detail and are particularly useful for surgical planning, especially for large paraprostatic cysts. They can delineate the relationship of the cyst to the urethra, bladder, and other pelvic structures. Urethrocystoscopy may be performed to evaluate the prostatic urethra and identify any communication with the cyst.

Cytology of cyst fluid obtained via FNA is an important diagnostic step. In sterile cysts, the fluid is typically clear, straw-colored, and acellular or contains few epithelial cells and macrophages. In infected cysts, the fluid may be turbid, purulent, and contain numerous degenerate neutrophils, bacteria, and cellular debris. Cytology can also help differentiate cysts from neoplasia, as neoplastic cells may be present in malignant effusions. Histopathology of prostatic tissue or cyst wall is the gold standard for definitive diagnosis. Prostatic cysts are lined by cuboidal or columnar epithelium, often with evidence of squamous metaplasia if estrogenic stimulation is present. Paraprostatic cysts may be lined by cuboidal, transitional, or fibrous tissue, depending on their origin. In cases of abscessation, there is extensive neutrophilic infiltration and necrosis. If neoplasia is present, histopathology can identify the tumor type and grade. Special stains, such as immunohistochemistry for cytokeratin or vimentin, may be used to differentiate epithelial from mesenchymal tumors.

Treatment of prostatic and paraprostatic cysts depends on the size, clinical signs, and presence of infection. For asymptomatic cysts, especially in intact males, castration is often recommended as it reduces androgen stimulation and may lead to regression of BPH-associated cysts. However, paraprostatic cysts may not regress after castration and may require surgical excision. Medical management with anti-androgens (e.g., finasteride, 0.1-0.5 mg/kg PO q24h) or GnRH agonists (e.g., deslorelin implant) can be used to reduce prostatic size, but these are not always effective for cysts. If the cyst is infected, appropriate antibiotic therapy based on culture and sensitivity is essential. Antibiotics that penetrate the prostate well, such as enrofloxacin (5-10 mg/kg PO q24h), clindamycin (5-10 mg/kg PO q12h), or trimethoprim-sulfamethoxazole (15-30 mg/kg PO q12h), should be used for at least 4-6 weeks. In cases of abscessation, surgical drainage or marsupialization may be necessary. For large paraprostatic cysts causing clinical signs, surgical excision is the treatment of choice. The cyst should be carefully dissected from surrounding tissues, and the stalk or communication with the prostate should be ligated. In some cases, partial prostatectomy may be required. Postoperative care includes pain management, antibiotics, and monitoring for complications such as urinary incontinence or recurrence. In cats, if the cyst is associated with a testicular tumor, castration is curative. Supportive care includes fluid therapy, nutritional support, and management of any urinary obstruction.

The prognosis for prostatic and paraprostatic cysts is generally good with appropriate treatment. For small, asymptomatic cysts, the prognosis is excellent, and many dogs live normal lives without intervention. For cysts causing clinical signs, surgical excision or castration often resolves the signs, and the prognosis is good. However, if the cyst is infected or abscessed, the prognosis is more guarded, especially if there is systemic illness or rupture. Recurrence is possible, particularly if the underlying cause (e.g., BPH) is not addressed. In cases of prostatic neoplasia, the prognosis is poor, with a median survival time of a few months. For paraprostatic cysts, surgical excision is usually curative, but there is a risk of complications such as urinary incontinence or urethral damage. Fertility may be affected if the prostate is significantly compromised, but many dogs can still breed successfully after treatment. Overall, early diagnosis and treatment improve the prognosis.

Follow-up care is essential to monitor for recurrence and complications. After castration, the prostate should gradually decrease in size over 8-12 weeks. Serial ultrasonography can be performed at 1, 3, and 6 months post-treatment to assess prostatic size and cyst resolution. If the cyst was surgically excised, recheck ultrasonography at 2-4 weeks postoperatively to ensure no fluid re-accumulation. Monitor for clinical signs such as dysuria, tenesmus, or recurrence of a palpable mass. If antibiotics were prescribed, a recheck culture may be indicated after completion of therapy to ensure resolution of infection. For dogs with BPH, periodic reproductive examinations, including semen evaluation, may be recommended if breeding is intended. In cats, post-castration monitoring is usually straightforward, with resolution of clinical signs expected within weeks. Long-term follow-up should include regular physical examinations and imaging if any new signs develop.

Clinical Pearls: - Always perform a rectal palpation in intact male dogs with lower urinary tract signs; a large, fluctuant prostate may indicate a cyst or abscess. - Ultrasonography is the most sensitive imaging modality for detecting prostatic cysts; use a high-frequency transducer for better resolution. - If a paraprostatic cyst is suspected, consider the possibility of a Mullerian duct remnant; surgical excision should be complete to prevent recurrence. - Castration is the first-line treatment for BPH-associated cysts; it is safe and effective in most cases. - For infected cysts, culture and sensitivity are crucial; choose antibiotics with good prostatic penetration and treat for at least 4-6 weeks. - In cats, always rule out testicular neoplasia in intact males with prostatic cysts. Pitfalls: - Do not mistake a prostatic abscess for a simple cyst; abscesses require aggressive treatment, including drainage and long-term antibiotics. - Avoid FNA of a suspected abscess without ultrasound guidance, as it may cause peritonitis if the cyst ruptures. - Do not delay surgical intervention for large paraprostatic cysts causing urinary obstruction; this is an emergency. - Be cautious with the use of anti-androgens in breeding animals, as they may affect fertility. - Do not assume that castration will resolve all paraprostatic cysts; some may be independent of hormonal stimulation and require surgery.

Current drug protocols for prostatic and paraprostatic cysts focus on managing BPH and treating infection. For BPH, finasteride (a 5-alpha-reductase inhibitor) is commonly used at a dose of 0.1-0.5 mg/kg PO q24h for 2-4 months. It reduces prostatic size without affecting libido or semen quality significantly. GnRH agonists, such as deslorelin (4.7 mg implant SC), can be used for long-term suppression of testosterone, but they may cause a temporary flare effect. For acute management of prostatic enlargement, osaterone acetate (0.25-0.5 mg/kg PO q24h for 7 days) is an anti-androgen used in some countries. Antibiotics for prostatitis include enrofloxacin (5-10 mg/kg PO q24h), clindamycin (5-10 mg/kg PO q12h), or trimethoprim-sulfamethoxazole (15-30 mg/kg PO q12h). These should be continued for 4-6 weeks. In cases of abscessation, surgical drainage is often necessary, and antibiotics should be based on culture. For pain management, NSAIDs such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) can be used, but caution is advised in patients with renal or hepatic disease. Supportive care includes fluid therapy and nutritional support. In cats, if a testosterone-secreting tumor is present, castration is curative, and no specific drug therapy is needed.

Evidence-based literature on prostatic and paraprostatic cysts is limited, but several studies provide guidance. A study by Johnston et al. (2000) in Canine and Feline Theriogenology reported that BPH is the most common prostatic disorder in intact male dogs, and cysts are a frequent complication. They recommended castration as the treatment of choice for BPH-associated cysts. Another study by Krawiec and Heflin (1992) evaluated the use of finasteride in dogs with BPH and found a significant reduction in prostatic volume after 12 weeks of treatment. A retrospective study by White et al. (1997) described the clinical features and surgical management of paraprostatic cysts in dogs, concluding that surgical excision is effective but may be associated with complications such as urinary incontinence. A more recent study by Smith (2008) in the BSAVA Manual of Canine and Feline Reproduction and Neonatology emphasized the importance of ultrasonography in diagnosing prostatic cysts and differentiating them from abscesses. The use of GnRH agonists for BPH has been supported by studies showing a decrease in prostatic size and clinical signs. Overall, the literature supports a stepwise approach: castration for BPH, antibiotics for infection, and surgery for large or symptomatic cysts. However, large prospective studies are needed to establish standardized protocols.